EML4-ALK在非小细胞肺癌中的检测及其临床意义被引量：1

Expression and clinical significance of EMIA-ALK in non-small cell lung cancer

导出

摘要棘皮动物微管结合蛋白4（EML4）与间变淋巴瘤激酶（ALK）形成的融合基因被认为是非小细胞肺癌（NSCLC）新的分子靶点。最近，Ⅰ期和Ⅱ期临床研究运用ALK抑制剂治疗携带重组ALK基因的NSCLC患者的反应率达80％以上。因此，研究EML4-ALK的生物学特性、与临床病理特征的关系以及目前存在的问题，可为临床治疗此类患者提供新的思路。 The fusion gene between echinoderm microtubule-associated protein-like 4 （EMIA and anaplastic lymphoma kinase （ALK） has recently been identified as a new molecular target of non-small cell lung cancers （NSCLC）. Stage Ⅰ and stage Ⅱ clinical trials have observed remarkably clinical efficacy of ALK inhibitors in NSCLC patients harboring EMIA-ALK translocations, with response rates exceeding 〉 80%. Investigation of EMIA-ALK＇s biological functions and its correlation with clinical characteristics may shed some light on a new treatment strategy for NSCLC.

作者马丽韩晓红石远凯

机构地区中国医学科学院肿瘤医院肿瘤研究所内科实验室

出处《国际肿瘤学杂志》 CAS 2011年第1期42-44,共3页 Journal of International Oncology

关键词癌非小细胞肺棘皮动物微管蛋白样4 Carcinoma, Non-small-cell lung Echinoderm microtubule-associated protein-like 4

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献9

1Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EMIA-ALK fusion gene in non-small-cell lung cancer. Nature, 2007, 448 (7153) :561-566.
2Sasaki T, Rodig SJ, Chirieac LR, et al. The biology and treatment of EMIA-ALK non-small cell lung cancer. Eur J Cancer, 2010, 46 (10) :1773-1780.
3Lin E, Li L, Guan Y, et al. Exon array profiling detects EMIA-ALK fusion in breast, colorectal and non-small cell lung cancers. Mol Cancer Res, 2009, 7 (9) : 1466-1476.
4Zhang X, Zhang S, Yang X, et al. Fusion of EMIA and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer, 2010, 9:185.
5Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Chn Cancer Res, 2008, 14 ( 13 ) :4275-4283.
6Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4- ALK. J Clin Oncol, 2009, 27(26) :4247-4253.
7Rodig SJ, Mino-Kenudson M, Daeie S, et al. Unique elinieopathologic features characterize ALK-rearranged lung adenoeareiuoma in the western population. Clin Cancer Res, 2009, 15 (16) :5216-5223.
8Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res, 2010,16(5) :1561-1571.
9Horn L, Pao W. EMIA-ALK : honing in on a new target in non-small- cell lung cancer. J Clin Oncol, 2009, 27(26) :4232-4235.